CSIC joins Tirecat Health as a shareholder

CSIC joins Tirecat Health as a shareholder

Bellaterra (Barcelona), September 2026 – The Spanish National Research Council (CSIC) has joined Tirecat Health as a shareholder, following a resolution of the CSIC President on 22 September 2026.

Both institutions behind RESKIN, now in the company

CSIC enters the company through a transfer of shares from the Catalan Institute of Nanoscience and Nanotechnology (ICN2). The two institutions co-own the patent family behind RESKIN (WO2022258780A1), which Tirecat Health licenses exclusively worldwide. With this step, both are now part of the company, alongside the founders and Criteria Capital Risc, of the “la Caixa” group.

The entry of CSIC strengthens the link between Tirecat Health and the research of the NANOSFUN group at ICN2-CSIC, where the technology was born, and recognises the role of public research in creating new deep-tech companies.

Part of the CSIC deep-tech ecosystem

On 9 October 2026, CSIC included Tirecat Health among the four new knowledge-based companies it is promoting, together with companies working in food safety, sustainable chemistry and precision agriculture. CSIC highlighted RESKIN, its bioinspired catecholamine membranes that adhere to tissue without sutures and have broad-spectrum antimicrobial activity, with applications in diabetic foot ulcers, burns and other wounds with a high health impact.

According to CSIC, two thirds of its more than 100 active knowledge-based companies have been created in the last seven years, with a survival rate of 82%. Read the CSIC news (in Spanish).

A stronger company for the next phase

Tirecat Health has also renewed its governance with a Board of Directors to lead the next phase: preparing the first clinical study of RESKIN in 2027.